比阿培南在高龄老年患者中的应用

doi:10.5246/jcps.2023.02.013

中国药学(英文版) ›› 2023, Vol. 32 ›› Issue (2): 145-152.DOI: 10.5246/jcps.2023.02.013

• 【药事管理与临床药学专栏】 • 上一篇下一篇

比阿培南在高龄老年患者中的应用

朱愿超¹, 陈晨², 胡欣¹^,^*()

1. 北京医院药学部国家老年医学中心中国医学科学院老年医学研究院北京市药物临床风险与个体化应用评价重点实验室(北京医院), 北京 100730
2. 山东大学第二医院药学部, 山东济南 250033

收稿日期:2022-07-24 修回日期:2022-09-08 接受日期:2022-10-11 出版日期:2023-02-28 发布日期:2023-02-28
通讯作者: 胡欣
作者简介:
+ Tel.: +86-10-85133636, E-mail: Huxinbjyy@126.com
基金资助:
National High Level Hospital Clinical Research Funding (Grant No. BJ-2022-173), Sentinel project of Shandong Adverse Drug Reaction Monitoring Center (Grant No. 2021SDADRKY04).

Retrospective analysis of biapenem treatment for bacterial infection in very elderly patients

Yuanchao Zhu¹, Chen Chen², Xin Hu¹^,^*()

1 Department of Pharmacy, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing Key Laboratory of Assessment of Clinical Drugs Risk and Individual Application (Beijing Hospital), Beijing 100730, China
2 Department of Pharmacy, The Second Hospital of Shandong University, Jinan 250033, Shandong, China

Received:2022-07-24 Revised:2022-09-08 Accepted:2022-10-11 Online:2023-02-28 Published:2023-02-28
Contact: Xin Hu

摘要/Abstract

摘要：

本研究旨在评估比阿培南在高龄老年患者(≥ 85岁)中的疗效和安全性, 为比阿培南的合理应用提供依据。对2016年1月至2017年12月入住我院接受比阿培南治疗的高龄患者进行回顾性分析。最终共纳入275名患者, 平均年龄为88.5 ± 3.1岁。感染治疗的总有效率为67.6%(186/275)。单因素回归分析分析显示, 发热、血清尿素氮(BUN)升高的患者治疗失败率更高, 而患者基础疾病类型、是否单药治疗、之前用药情况、丙氨酸转氨酶(ALT)、天冬氨酸转氨酶(AST)等指标与临床治疗结果没有显著相关性。将发热、BUN升高纳入多因素回归分析, 结果表明发热和BUN升高是影响治疗结果的独立危险因素。安全性方面, 比阿培南治疗后血清BUN由8.8 ± 5.6升至9.9 ± 5.4 mmol/L (P = 0.007)。有10.9% (30/275)的患者出现轻中度药物不良反应。本研究证明比阿培南可安全有效的应用于高龄老年患者。

关键词: 比阿培南, 细菌感染, 高龄老年人, 疗效, 安全性

Abstract:

In the present study, we aimed to evaluate the efficacy and safety of biapenem in very elderly (≥ 85 years) patients. A retrospective study was conducted on very elderly patients who received biapenem for at least 72 h and had a complete medical record from January 2016 to December 2017. Baseline characteristics and laboratory test results were recorded and assessed. Finally, 275 unique patients with an average age of 88.5 ± 3.1 years were enrolled. Of these patients, 186 (67.6%) had successful treatment. Univariate analysis of various parameters showed that fever and BUN (serum urea nitrogen) elevation were associated with treatment failure. In contrast, other parameters showed no significant differences between the treatment success group and treatment failure group, which included primary underlying disease, monotherapy, prior use of antibiotics, alanine aminotransferase (ALT), aspartate aminotransferase (AST). Multivariate logistic regression analysis found that fever and BUN elevation were independent risk factors for treatment outcomes. BUN was elevated from 8.8 ± 5.6 to 9.9 ± 5.4 mmol/L after treatment (P = 0.007). Adverse drug reactions were observed in 10.9% (30/275) of patients, and all of these were mild or intermediate. The study suggested that biapenem was efficacious and safe in very elderly patients (≥ 85 years).

Key words: Biapenem, Bacterial infection, Very elderly, Clinical efficacy, Clinical safety

Supporting:

朱愿超, 陈晨, 胡欣. 比阿培南在高龄老年患者中的应用[J]. 中国药学(英文版), 2023, 32(2): 145-152.

Yuanchao Zhu, Chen Chen, Xin Hu. Retrospective analysis of biapenem treatment for bacterial infection in very elderly patients[J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(2): 145-152.

图/表 5

Table 1. Clinical characteristics of 275 patients treated with biapenem. Univariate analysis of factors associated with clinical outcomes.

Table 2. Body weight-related clinical characteristics. Univariate analysis of factors associated with clinical outcome.

Table 3. Multivariable logistic regression analysis of factors associated with biapenem treatment failure.

Table 4. Effect of biapenem on liver and kidney function (n = 275).

Table 5. Microbiological data of patients. Univariate analysis of factors associated with clinical outcome, n (%).

参考文献 15

[1]	Perry, C.M.; Ibbotson, T. Biapenem. Drugs. 2002, 62, 2221–2234; discussion 2235.
[2]	Malanoski, G.J.; Collins, L.; Wennersten, C.; Moellering, R.C. Jr, Eliopoulos, G.M. In vitro activity of biapenem against clinical isolates of gram-positive and gram-negative bacteria. Antimicrob. Agents Chemother. 1993, 37, 2009–2016.
[3]	Hikida, M.; Kawashima, K.; Yoshida, M.; Mitsuhashi, S. Inactivation of new carbapenem antibiotics by dehydropeptidase-I from porcine and human renal cortex. J. Antimicrob. Chemother. 1992, 30, 129–134.
[4]	Hori, S.; Kanemitsu, K.; Shimada, J. Relation between convulsant activity of biapenem, a new carbapenem, and its binding affinity to GABA receptor. Chemotherapy. 1994, 42, 115–120.
[5]	Writing Group of Guidance for Clinical Trials of Anti-bacterial Drugs. Guidance for Clinical Trials of Anti-bacterial Drugs. Chin. J. Clin. Pharmacol. 2014, 30, 844–856.
[6]	National Health and Family Planning Commission of the People’s Republicof China, State Administration of Traditional Chinese Medicine of the People’s Republic of China, Medical Department Of the People’s Liberation Army General Logistics Department. Guideline principles for clinical use of antibiotics. (version 2015)[S] Beijing, 2015.
[7]	Kozawa, O.; Uematsu, T.; Matsuno, H.; Niwa, M.; Takiguchi, Y.; Matsumoto, S.; Minamoto, M.; Niida, Y.; Yokokawa, M.; Nagashima, S.; Kanamaru, M. Pharmacokinetics and safety of a new parenteral carbapenem antibiotic, biapenem (L-627), in elderly subjects. Antimicrob. Agents Chemother. 1998, 42, 1433–1436.
[8]	Zhu, X.; Sun, Y.X.; He, X.J.; Qiu, F.; Li, L.; Zhao, L.M. HPLC-UV method with solid-phase extraction for the quantitative determination of biapenem in human plasma and its application in pharmacokinetic study. J. Chin. Pharm. Sci. 2011, 20, 70–76.
[9]	Burton, D.G.A.; Allen, M.C.; Bird, J.L.E.; Faragher, R.G.A. Bridging the gap: ageing, pharmacokinetics and pharmacodynamics. J. Pharm. Pharmacol. 2005, 57, 671–679.
[10]	Wang, X.H.; Zhang, X.K.; Zong, Z.Y.; Yu, R.J.; Lv, X.J.; Xin, J.B.; Tong, C.H.; Hao, Q.L.; Qin, Z.Q.; Xiong, Y.; Liu, H.; Ding, G.H.; Hu, C.P.; Group, B.S.C. Biapenem versus meropenem in the treatment of bacterial infections: a multicenter, randomized, controlled clinical trial. Indian J. Med. Res. 2013, 138, 995–1002.
[11]	Jia, B.; Lu, P.; Huang, W.X.; Li, C.Z.; Huang, A.L.; Zhou, X.D.; Zhang, W.L.; Wu, G.M.; Zhang, G.F. A multicenter, randomized controlled clinical study on biapenem and imipenem/cilastatin injection in the treatment of respiratory and urinary tract infections. Chemotherapy. 2010, 56, 285–290.
[12]	Dong, J.; Chen, Y.C.; Xiong, W.; Zhao, Y.F.; Sun, Y.B.; Lu, Y.; Liu, Y.H.; Li, W.Y.; Chen, X.J. Efficacy and safety of biapenem against lower respiratory tract infections in elderly Chinese patients and optimal dosing regimen based on pharmacokinetic/pharmacodynamic analysis. J. Chemother. 2016, 28, 403–410.
[13]	Zhang, Z.X.; Yong, Y.; Tan, W.C.; Shen, L.; Ng, H.S.; Fong, K.Y. Prognostic factors for mortality due to pneumonia among adults from different age groups in Singapore and mortality predictions based on PSI and CURB-65. Singapore Med. J. 2018, 59, 190–198.
[14]	Beier, K.; Eppanapally, S.; Bazick, H.S.; Chang, D.; Mahadevappa, K.; Gibbons, F.K.; Christopher, K.B. Elevation of blood urea nitrogen is predictive of long-term mortality in critically ill patients independent of "normal" creatinine. Crit. Care Med. 2011, 39, 305–313.
[15]	Uranga, A.; Quintana, J.M.; Aguirre, U.; Artaraz, A.; Diez, R.; Pascual, S.; Ballaz, A.; España, P.P. Predicting 1-year mortality after hospitalization for community-acquired pneumonia. PLoS One. 2018, 13, e0192750.

比阿培南在高龄老年患者中的应用

Retrospective analysis of biapenem treatment for bacterial infection in very elderly patients

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 5

参考文献 15

相关文章 15

编辑推荐

Metrics

本文评价

[1]	杨晗春, 成斐, 黄娟娟. 艾曲波帕对难治性原发免疫性血小板减少症的疗效及其对细胞免疫功能的影响[J]. 中国药学(英文版), 2023, 32(9): 736-743.
[2]	蔺长平, 汪三岳, 薛允国, 俞游柳. 咪唑安定复合地佐辛在腹腔镜阑尾切除术中的效果评估[J]. 中国药学(英文版), 2023, 32(3): 207-213.
[3]	袁叶, 李亚男, 赵晴, 于博, 杨秀岭. 基于PK/PD模型和蒙特卡洛模拟评价头孢曲松给药方案[J]. 中国药学(英文版), 2022, 31(5): 382-388.
[4]	佟盟, 詹威, 牛铖铖, 葛泽梅, 李润涛, 王欣. 利用连续流动反应一锅法合成不对称芳香脲的Curtius重排反应[J]. 中国药学(英文版), 2022, 31(12): 938-945.
[5]	孙星, 杨昌永, 林侃, 周彩红, 廖成, 张利敏, 金薪盛, 毛浪勇, 应华, 陶维康, 张连山. 卡瑞利珠单抗, 一种人源化抗PD-1 IgG4亚型单克隆抗体在临床前研究中表现出优异的抗肿瘤活性以及良好的安全性[J]. 中国药学(英文版), 2021, 30(5): 393-408.
[6]	李春杏, 朱元明, 刘桦, 徐钊. 促动力药联合质子泵抑制剂与单独质子泵抑制剂治疗胃食管反流疾病疗效的荟萃分析[J]. 中国药学(英文版), 2021, 30(4): 347-356.
[7]	周艳, 宋恒文, 邵志超, 尹博民, 付西美, 谢典佑, 韦利军. 一种新的细胞周期蛋白依赖性激酶(CDK)9抑制剂QHRD107对急性髓系白血病的临床前疗效[J]. 中国药学(英文版), 2021, 30(2): 146-156.
[8]	陈倩, 赵旭阳, 宋宇靖, 李少一, 雷婉钰, 马维宁, 黄卓. 鉴定用于评估切除性癫痫手术后癫痫发作情况的血清生物标志物[J]. 中国药学(英文版), 2020, 29(8): 528-541.
[9]	杨东升, 马玲云, 牛剑钊, 许鸣镝. 美国授权仿制药应用简介[J]. 中国药学(英文版), 2019, 28(6): 439-445.
[10]	杨东升, 马玲云, 牛剑钊, 许鸣镝. 美国国家药品编码应用简介[J]. 中国药学(英文版), 2019, 28(3): 203-208.
[11]	胡岚岚, 周娟, 邹欢, 张玥, 汤建林. 抗癫痫药物左乙拉西坦注射液和口服片剂在中国健康志愿者中的药动学、安全性和生物等效性研究 [J]. 中国药学(英文版), 2018, 27(11): 777-786.
[12]	牛剑钊, 杨东升, 许鸣镝. 欧盟仿制药参比制剂检索与确认简介[J]. 中国药学(英文版), 2018, 27(11): 805-812.
[13]	肖锐锐, 徐秀琴, 孙磊, 方晓磊, 肖鹏. 降心率药物伊伐布雷定安全性的系统评价[J]. 中国药学(英文版), 2017, 26(5): 379-389.
[14]	林志燕, 田怀平, 李方, 秦丽萍, 张欣, 陆晓彤. 舒肝祛脂胶囊治疗成人单纯性肥胖的临床疗效及安全性评价[J]. 中国药学(英文版), 2017, 26(12): 890-894.
[15]	谢红军, 刘磊, 曾凡, 沐黎敏, 赵曜, 阎妍, 胡英杰, 吴佳栓, 卜英子, 张婧莹, 吕万良. 抗耐药长春瑞滨脂质体及其抗耐药性乳腺癌的效应与机制研究[J]. 中国药学(英文版), 2016, 25(7): 489-501.